Human Rabies Vaccine Market

The global human rabies market size is projected to register a substantial CAGR during the forecast period, 2021-2028 attributed to the increasing number of pets, pets having a low immunization rate, and increasing friendliness of the public with pets. Moreover, the rising geriatric population base having low immunity is also expected to drive market growth.

Get Free Sample Report

A virus that is deadly and which spreads to people from the saliva of infected animals is known as rabies. It usually happens when an individual is bitten or scratched by an animal, for instance, stray dogs. The common symptoms of rabies include excess salivation, headache, mental confusion, fever, paralysis, and muscle spasms. The other symptoms of rabies also include difficulty in respiration and hydrophobia. There is no specific treatment available for rabies; however, the infection can be prevented by using a vaccine. The symptoms of rabies may occur delay and could cause deadly effects. Therefore, the person who is bitten by an animal should be taken to the hospital or clinics immediately to administer human rabies vaccine. As per the reports by the World Health Organization (WHO), in 2015 about 99% of rabies cases were reported due to domestic dogs bite. Other animals whose scratch or contact of saliva causes rabies include cats, raccoons, bats, skunks, and foxes. More than 40% of people suffering from rabies are children under the age of 15. In the US, the most number of deaths due to rabies was caused by bats.

The COVID-19 pandemic outbreak had resulted a positive impact on the market. The reports by the Centers for Disease Control and Prevention (CDC) in 2020 suggested that animals such as dogs, cats, and others were at a great risk to be affected by SARS-CoV-2. Several studies are also been taken to understand the correlation of transmission of this deadly infection between humans and animals. A study published by the Nature magazine in October 2020 stated that a highly efficient, novel, and safe vaccine for COVID-19 could be developed using a rabies virus-based vector.

Market Trends, Drivers, Restraints, and Opportunities

• Globally, rise in the number of deaths caused due to rabies is anticipated to fuel the market growth during the forecast period.
• Presence of a large population of stray dogs and issues increasing related to them in low & middle-income countries are expected to propel the market growth.
• Increasing services for pet management and technological advancement are anticipated to drive the market expansion in the coming years.
• Absence of awareness in public and negligence showed by them are key challenges that can restrain the market growth over the forecast period.
• Increasing government initiatives and wide introduction or development of human rabies vaccines are projected to create lucrative opportunities for market growth.

Scope of the Report

The report on the global human rabies vaccine market includes an assessment of the market, trends, and segments. Overview and dynamics have also been included in the report.

Market Segment Insights

Post-Exposure prophylaxis segment is expected to grow at a significant rate

On the basis of products, the global human rabies market is bifurcated into pre-exposure vaccination and post-exposure prophylaxis. The pre-exposure vaccination segment is projected to hold a key market share during the forecast period as it is widely given to individuals who are most likely to get infected by rabies such as wildlife officers, veterinarians, and people traveling to countries that have increased risk of rabies infection. However, the post-exposure prophylaxis segment is expected to grow at a significant rate in the coming years as it is given to an individual when they are bitten by an animal that is suspected to be rabid.

Get Free Sample Report

North America is anticipated to dominate the market

In terms of regions, the market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is anticipated to dominate the market during the projected period attributed to the presence of healthcare infrastructure that is well established, high awareness among healthcare professionals, and increasing initiatives by the government towards awareness of rabies. North America is followed by Europe with a very thin difference. The driving factors of the market in Europe are the presence of primary manufacturers in the region and increasing research & development activities for the development of vaccines that are more efficient. On the other hand, the market in Asia Pacific is estimated to expand at a rapid pace in the coming years owing to the presence of the wide number of domesticated animal population in the region.

Get Free Sample Report

Segments

• Pre-Exposure Vaccination
• Post-Exposure Prophylaxis

• Asia Pacific
• North America
• Latin America
• Europe
• Middle East & Africa

• Medimmune LLC.
• Novartis Vaccines and Diagnostics Ltd.
• GlaxoSmithKline Biologicals
• Cadila Pharmaceuticals Ltd.
• Merck & Co Inc.
• Berna Biotech Ltd.
• Sanofi Pasteur, Inc.
• Wyeth pharmaceuticals

Competitive Landscape

Key players competing in the global human rabies vaccine market are Medimmune LLC.; Novartis Vaccines and Diagnostics Ltd.; GlaxoSmithKline Biologicals; Cadila Pharmaceuticals Ltd.; Merck & Co Inc.; Berna Biotech Ltd.; Sanofi Pasteur, Inc.; and Wyeth pharmaceuticals. Many of these players have adopted business strategies such as the launch of new products, the advancement of technologies, mergers, partnerships, and production capacity expansion to increase their market position and expand their consumer base globally.